Could a common antioxidant help sepsis patients with liver damage?

NCT ID NCT07273071

Not yet recruiting Disease control Sponsor: Theis S. Itenov Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a single dose of N-acetylcysteine (NAC), an antioxidant, can help adults with severe infections and liver dysfunction recover faster. 360 participants will receive either NAC or a placebo infusion within 24 hours of hospital admission. The main goal is to see if NAC increases the number of days patients are alive and out of the hospital within the first two weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: N-acetylcysteine (NAC)
What this could lead to: If it works, this could provide a simple, widely available treatment to improve survival and shorten hospital stays for sepsis patients with liver issues.
What could go wrong: This is a relatively small, early-stage trial (360 participants) testing a short-term infusion. The drug may not improve outcomes and could cause allergic reactions or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Infections infectious disease infectious disease with sepsis liver disorder Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE INFECTION SEPSIS SEVERE INFECTION

Contacts and locations

Locations

Department of Emergency Medicine, Copenhagen University Hospital - Bispebjerg and Frederiksberg

Copenhagen, 2400, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.